GlassScriptPhysician profile
James Mirabile
NPI 1588608855
$8,600.52
in general payments reported to CMS, 2019-2025
35 companies · $491 in 2025
The $491 reported for 2025 was more than what 80% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $793 · 2020: $999 · 2021: $2,156 · 2022: $1,925 · 2023: $1,502 · 2024: $733 · 2025: $491.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,709 · Education: $17.46.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,709.13 |
| Education | $17.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,141.18 | 2019-2025 | |
| Pfizer INC. | $1,029.63 | 2019-2024 | |
| Galderma Laboratories, L.P. | $629.79 | 2019-2025 | Dysport |
| Avion Pharmaceuticals | $525.11 | 2019-2022 | |
| Mayne Pharma Commercial LLC | $437.05 | 2021-2025 | |
| Allergan, INC. | $315.81 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $298.70 | 2023-2025 | Gemtesa, Myfembree |
| Eisai INC. | $227.03 | 2020-2021 | |
| Astellas Pharma US INC | $225.15 | 2019-2025 | Veozah |
| Biohaven Pharmaceutical Holding Company LTD. | $219.62 | 2022 | |
| Lilly USA, LLC | $151.00 | 2021-2025 | Zepbound |
| Myovant Sciences INC. | $150.28 | 2021-2022 | |
| Therapeuticsmd, INC. | $136.52 | 2021-2022 | |
| Urovant Sciences INC | $118.98 | 2021-2022 | |
| Horizon Therapeutics Plc | $112.75 | 2019-2021 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $112.22 | 2020-2023 | Linzess |
| Millicent US INC | $71.56 | 2024-2025 | Intrarosa, Femring, Femlyv |
| Bausch Health US, LLC | $67.20 | 2019-2022 | |
| Merz North America, INC. | $62.47 | 2019 | |
| Virtus Pharmaceuticals LLC | $60.46 | 2021 | |
| Endo Pharmaceuticals INC. | $57.07 | 2019-2020 | |
| Hologic Sales and Service, LLC | $56.77 | 2019-2023 | Thinprep 2000 Processor, Third Wave, Aptima |
| Exeltis, USA INC. | $56.60 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $52.44 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $52.34 | 2021 | |
| Evofem Biosciences, INC. | $48.12 | 2021 | |
| Amag Pharmaceuticals, INC. | $30.13 | 2019 | |
| Acelrx Pharmaceuticals, INC. | $23.21 | 2021 | |
| Idorsia Pharmaceuticals US INC | $22.97 | 2022 | |
| Assertio Therapeutics, INC. | $22.82 | 2020 | |
| Agile Therapeutics, INC. | $20.41 | 2021 | |
| Acella Pharmaceuticals, LLC | $19.03 | 2024 | NP Thyroid 60 |
| Musculoskeletal Transplant Foundation INC. | $17.41 | 2023 | |
| Dexcom, INC. | $17.34 | 2025 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $11.35 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Mirabile listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.